CIK 0001842295 · Non-accelerated filer<br>Emerging growth company
Maze Therapeutics, Inc.
Sign in to watch- Ticker
- MAZE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6508505070
- Business address
- 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,785,701
- in 13 filings, $4.6M under 10b5-1 plans
Net −$5,785,701. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-01 | Dandekar Atul CSBO | Option exercise · Restricted Stock Units | −12,500 | 12,500 | ||
| 2026-09-01 | Courtney Phillips GC and Corp. Secretary | Option exercise | +11,000 | 11,000 | ||
| 2026-09-01 | Courtney Phillips GC and Corp. Secretary | Option exercise · Restricted Stock Units | −11,000 | 11,000 | ||
| 2026-09-01 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −2,593 | $26.31 | $68K | 18,151 |
| 2026-09-01 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −31,908 | $26.29 | $839K | 223,355 |
| 2026-09-01 | Coloma Jason V Chief Executive Officer | Option exercise 10b5-1 | +50,000 | 50,000 | ||
| 2026-09-01 | Coloma Jason V Chief Executive Officer | Option exercise · Restricted Stock Units 10b5-1 | −50,000 | 50,000 | ||
| 2026-08-28 | Dandekar Atul CSBO | Option exercise 10b5-1 | +7,500 | $10.42 | $78K | 33,750 |
| 2026-08-28 | Dandekar Atul CSBO | Sale 10b5-1 | −7,500 | $27.58 | $207K | 26,250 |
| 2026-08-28 | Dandekar Atul CSBO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,500 | 14,143 | ||
| 2026-08-13 | Kornowski Sophie Director | Grant or award · Stock Option (Right to Buy) | +36,000 | 36,000 | ||
| 2026-08-13 | Johnson Paula A Director | Grant or award · Stock Option (Right to Buy) | +36,000 | 36,000 | ||
| 2026-08-13 | Bernstein Harold President, R&D & CMO | Option exercise 10b5-1 | +16,142 | $10.42 | $168K | 16,142 |
| 2026-08-13 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −16,142 | $27.61 | $446K | 0 |
| 2026-08-13 | Bernstein Harold President, R&D & CMO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −16,142 | 176,803 | ||
| 2026-08-03 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −2,439 | $26.71 | $65K | 20,898 |
| 2026-08-03 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −154 | $27.09 | $4K | 20,744 |
| 2026-08-03 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −30,304 | $26.71 | $810K | 256,867 |
| 2026-08-03 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −1,604 | $27.09 | $43K | 255,263 |
| 2026-07-29 | Dandekar Atul CSBO | Option exercise 10b5-1 | +7,500 | $10.42 | $78K | 33,750 |
Page 3 of 14 · 267 trades